Over-using chemotherapy in the adjuvant setting

Research output: Contribution to journalArticle

Abstract

Avoidance of unnecessary or ineffective treatment should be one of the main goals in adjuvant breast oncology today. Unfortunately, both patients and doctors hunt for tiny statistical differences in survival curves. This search could not only lead to an oncological approach of unlimited addition that we will not be able to afford, but would also end inevitably in indeterminate overtreatment with substantial risks of unexpected toxic effects eating away whatever progress we might make. “Do not harm” remains the main principle in medicine. To be able to follow this rule, we need to better understand the biology of breast cancer. The mistake of “one treatment fits all” can only be changed when we critically review trial designs of adjuvant breast oncology. The risk of overtreatment is there and selection of precisely defined cohorts for phase 3 trials is necessary, despite pressure of scientific ambition, pragmatism, and demands of industry. The “add on” clinical trial design model accepts the inability to confirm that standard therapy is still necessary if a positive result from the addition of the new therapy is obtained. The same model can be applied to “extended” adjuvant treatments in breast cancer subtypes. Addition of “miraculin” to the standard of care should generate a new standard. Such trials that show a modest benefit on average at a population level take us a step away from refining care for the individual, and might support the use of multiple and costly interventions with potential short and long term side effects. It is essential to escalate treatment when necessary and to de-escalate when un-necessary.

Original languageEnglish
Pages (from-to)303-308
Number of pages6
JournalBreast
Volume31
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Adjuvant Chemotherapy
Breast
Therapeutics
Breast Neoplasms
Poisons
Standard of Care
Industry
Eating
Medicine
Clinical Trials
Pressure
Survival
Population

Keywords

  • Adjuvant chemotherapy
  • Early breast cancer
  • Overtreatment

ASJC Scopus subject areas

  • Surgery

Cite this

Over-using chemotherapy in the adjuvant setting. / Curigliano, Giuseppe; Criscitiello, Carmen; Esposito, Angela; Pruneri, Giancarlo.

In: Breast, Vol. 31, 01.02.2017, p. 303-308.

Research output: Contribution to journalArticle

@article{deaa6502e76b40a7a8d66f486edf40aa,
title = "Over-using chemotherapy in the adjuvant setting",
abstract = "Avoidance of unnecessary or ineffective treatment should be one of the main goals in adjuvant breast oncology today. Unfortunately, both patients and doctors hunt for tiny statistical differences in survival curves. This search could not only lead to an oncological approach of unlimited addition that we will not be able to afford, but would also end inevitably in indeterminate overtreatment with substantial risks of unexpected toxic effects eating away whatever progress we might make. “Do not harm” remains the main principle in medicine. To be able to follow this rule, we need to better understand the biology of breast cancer. The mistake of “one treatment fits all” can only be changed when we critically review trial designs of adjuvant breast oncology. The risk of overtreatment is there and selection of precisely defined cohorts for phase 3 trials is necessary, despite pressure of scientific ambition, pragmatism, and demands of industry. The “add on” clinical trial design model accepts the inability to confirm that standard therapy is still necessary if a positive result from the addition of the new therapy is obtained. The same model can be applied to “extended” adjuvant treatments in breast cancer subtypes. Addition of “miraculin” to the standard of care should generate a new standard. Such trials that show a modest benefit on average at a population level take us a step away from refining care for the individual, and might support the use of multiple and costly interventions with potential short and long term side effects. It is essential to escalate treatment when necessary and to de-escalate when un-necessary.",
keywords = "Adjuvant chemotherapy, Early breast cancer, Overtreatment",
author = "Giuseppe Curigliano and Carmen Criscitiello and Angela Esposito and Giancarlo Pruneri",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.breast.2016.11.011",
language = "English",
volume = "31",
pages = "303--308",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Over-using chemotherapy in the adjuvant setting

AU - Curigliano, Giuseppe

AU - Criscitiello, Carmen

AU - Esposito, Angela

AU - Pruneri, Giancarlo

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Avoidance of unnecessary or ineffective treatment should be one of the main goals in adjuvant breast oncology today. Unfortunately, both patients and doctors hunt for tiny statistical differences in survival curves. This search could not only lead to an oncological approach of unlimited addition that we will not be able to afford, but would also end inevitably in indeterminate overtreatment with substantial risks of unexpected toxic effects eating away whatever progress we might make. “Do not harm” remains the main principle in medicine. To be able to follow this rule, we need to better understand the biology of breast cancer. The mistake of “one treatment fits all” can only be changed when we critically review trial designs of adjuvant breast oncology. The risk of overtreatment is there and selection of precisely defined cohorts for phase 3 trials is necessary, despite pressure of scientific ambition, pragmatism, and demands of industry. The “add on” clinical trial design model accepts the inability to confirm that standard therapy is still necessary if a positive result from the addition of the new therapy is obtained. The same model can be applied to “extended” adjuvant treatments in breast cancer subtypes. Addition of “miraculin” to the standard of care should generate a new standard. Such trials that show a modest benefit on average at a population level take us a step away from refining care for the individual, and might support the use of multiple and costly interventions with potential short and long term side effects. It is essential to escalate treatment when necessary and to de-escalate when un-necessary.

AB - Avoidance of unnecessary or ineffective treatment should be one of the main goals in adjuvant breast oncology today. Unfortunately, both patients and doctors hunt for tiny statistical differences in survival curves. This search could not only lead to an oncological approach of unlimited addition that we will not be able to afford, but would also end inevitably in indeterminate overtreatment with substantial risks of unexpected toxic effects eating away whatever progress we might make. “Do not harm” remains the main principle in medicine. To be able to follow this rule, we need to better understand the biology of breast cancer. The mistake of “one treatment fits all” can only be changed when we critically review trial designs of adjuvant breast oncology. The risk of overtreatment is there and selection of precisely defined cohorts for phase 3 trials is necessary, despite pressure of scientific ambition, pragmatism, and demands of industry. The “add on” clinical trial design model accepts the inability to confirm that standard therapy is still necessary if a positive result from the addition of the new therapy is obtained. The same model can be applied to “extended” adjuvant treatments in breast cancer subtypes. Addition of “miraculin” to the standard of care should generate a new standard. Such trials that show a modest benefit on average at a population level take us a step away from refining care for the individual, and might support the use of multiple and costly interventions with potential short and long term side effects. It is essential to escalate treatment when necessary and to de-escalate when un-necessary.

KW - Adjuvant chemotherapy

KW - Early breast cancer

KW - Overtreatment

UR - http://www.scopus.com/inward/record.url?scp=85006978060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006978060&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2016.11.011

DO - 10.1016/j.breast.2016.11.011

M3 - Article

AN - SCOPUS:85006978060

VL - 31

SP - 303

EP - 308

JO - Breast

JF - Breast

SN - 0960-9776

ER -